A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies Followed by 52 Week Open-Label Treatment

Trial Profile

A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies Followed by 52 Week Open-Label Treatment

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Ganaxolone (Primary)
  • Indications Epilepsy
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Marinus Pharmaceuticals
  • Most Recent Events

    • 23 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology
    • 23 Jan 2017 According to Marinus Pharmaceuticals media release, EEG data from one CDKL5 and two PCDH19 patients treated in this study presented at the annual meeting of the American Epilepsy Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top